Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis

Sci Rep. 2022 Feb 16;12(1):2623. doi: 10.1038/s41598-022-06689-4.

Abstract

Early diagnosis of colorectal advanced neoplasms (ANs), including colorectal cancer (CRC) and advanced adenoma (AA), has a positive effect on the survival rate. As a first attempt, the aim of this meta-analysis was to compare the diagnostic accuracy of faecal protein biomarkers for the detection of colorectal neoplasms with consideration of a wide range of covariates. A systematic literature search was performed up to Jun 10, 2021 on Web of Sciences, Scopus and PubMed. The diagnostic accuracies were calculated using the bivariate/hierarchical random effect model. Biomarkers were determined to be clinically applicable (CA) if they had areas under the curve > 0.70 and positive and negative likelihood ratios > 2 and < 0.5, respectively. A total of 47,059 test results were extracted from 16 immunochemical faecal occult blood test (iFOBT), 26 pyruvate kinase-M2 (PK-M2) and 23 faecal calprotectin (FC) studies. Only iFOBT, PK-M2 and FC for CRC plus iFOBT and PK-M2 for AN were CA. iFOBT had significantly superior accuracy (P = 0.02 versus PK-M2 and P < 0.01 versus FC for CRC; P < 0.01 versus PK-M2 for AN). Regarding covariates, the lateral flow method of PK-M2 measurement increased its accuracy for CRC detection compared to the enzyme-linked immunosorbent assay (P < 0.01). iFOBT is recommended as the most accurate faecal biomarker for CRC and AN diagnosis.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adenoma / diagnosis*
  • Adult
  • Aged
  • Biomarkers / analysis
  • Biomarkers, Tumor / analysis*
  • Colorectal Neoplasms / diagnosis*
  • Early Detection of Cancer / methods*
  • Enzyme-Linked Immunosorbent Assay
  • Feces / chemistry*
  • Female
  • Humans
  • Leukocyte L1 Antigen Complex / analysis
  • Male
  • Middle Aged
  • Occult Blood
  • Pyruvate Kinase / analysis*
  • Sensitivity and Specificity

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • Leukocyte L1 Antigen Complex
  • Pyruvate Kinase